3Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in betathalassaemia. Lancet, 2002,360(9332):516-520.
4Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia.Hematology, 2004:14-34.
5Wonke B. Clinical management of beta-thalassemia major. Semin Hematol, 2001,38 (4) : 350-359.
6Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.Haematologica, 2003, 88(5) :489-496.
7Shalev O, Hileti D, Nortey P, et al. Transport of 14Cdeferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol, 1999, 105(4):1081-1083.
8Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.Blood, 2003,102(5) : 1583-1587.
9Wu KH, Chang JS, Tsai CH,et al.Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol, 2004, 83(7) :471-473.
10Tsironi M, Deftereos S, Andriopoulos P, et al. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol, 2005, 74(1):84-85.
